Skip to main content
    P

    Phathom Pharmaceuticals Inc (PHAT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.50
    +0.10 (+1.35%)

    Market Cap: $598.67M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(16/28)
    Avg Surprise
    -2.25%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.04
    Range$-0.01 - $0.07
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.05-25.8%
    60d ago$0.04-12.9%
    30d ago$0.04+2.2%
    7d ago$0.040.0%
    Current$0.04
    Revenue Consensus
    $86M
    Range$82M - $88M
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.22
    Range$0.14 - $0.29
    5 analysts
    Revenue Consensus
    $101M
    Range$98M - $108M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.22---
    Sep 26EST
    		-$0.04---
    Jun 26
    Reported Jul 30
    		$-0.08$-0.15+46.67%Beat+91.1%
    Mar 26
    Reported Apr 30
    		$-0.18N/A+53.81%Beat+83.2%
    Dec 25
    Reported Feb 26
    		$-0.16$-0.20+20.00%Beat+84.8%
    Sep 25
    Reported Oct 30
    		$-0.15N/A+63.41%Beat+85.7%
    Jun 25
    Reported Aug 7
    		$-0.90$-0.86-4.65%Miss+28.0%
    Mar 25
    Reported May 1
    		$-1.07$-1.07-0.38%Miss+3.6%
    Dec 24
    Reported Mar 6
    		$-1.05$-1.08+2.78%Beat+24.5%
    Sep 24
    Reported Nov 7
    		$-1.05$-1.46+28.08%Beat-38.2%
    Jun 24
    Reported Aug 8
    		$-1.25$-1.24-0.81%Miss-48.8%
    Mar 24
    Reported May 9
    		$-1.11$-1.22+9.02%Beat-24.7%
    Dec 23
    Reported Mar 7
    		$-1.39$-1.08-28.70%Miss-4.5%
    Sep 23
    Reported Nov 9
    		$-0.76$-0.96+20.83%Beat+42.4%
    Jun 23
    Reported Aug 10
    		$-0.84$-0.95+11.58%Beat+36.8%
    Mar 23
    Reported May 10
    		$-0.89$-1.28+30.47%Beat+16.8%
    Dec 22
    Reported Feb 28
    		$-1.33$-1.35+1.48%Beat-40.0%
    Sep 22
    Reported Nov 8
    		$-1.32$-1.33+0.75%Beat-34.7%
    Jun 22
    Reported Aug 2
    		$-1.33$-1.11-19.82%Miss-33.0%
    Mar 22
    Reported May 10
    		$-1.07$-1.02-4.90%Miss-11.5%
    Dec 21
    Reported Mar 1
    		$-0.95$-1.03+7.77%Beat+39.9%
    Sep 21
    Reported Nov 8
    		$-0.98$-1.03+4.85%Beat+3.9%
    Jun 21
    Reported Aug 10
    		$-1.00$-0.99-1.01%Miss-56.3%
    Mar 21
    Reported May 11
    		$-0.96$-1.19+19.33%Beat-54.8%
    Dec 20
    Reported Mar 30
    		$-1.58$-1.12-41.07%Miss+60.2%
    Sep 20
    Reported Nov 10
    		$-1.02$-0.67-52.24%Miss+72.6%
    Jun 20
    Reported Aug 6
    		$-0.64$-0.62-3.23%Miss-
    Mar 20
    Reported May 12
    		$-0.62$-0.72+13.89%Beat-
    Dec 19
    Reported Mar 19
    		$-3.97$-1.25-217.60%Miss-
    Sep 19
    Reported Oct 28
    		$-3.72$-3.02-23.18%Miss-

    Key Metrics

    Valuation
    P/E Ratio-13.16EV/EBITDAN/A
    Price/FCF-17.02xFCF Yield-5.88%
    Profitability
    Profit Margin-41.30%Operating Margin-5.34%
    ROE-3489.00%ROIC18.25%
    Financial Health
    Debt/Equity-0.48xInterest Coverage-0.65x
    Current Ratio1.92xQuick Ratio1.87x
    Trading Statistics
    Beta0.50Avg Volume1.41M
    52-Week High$18.3152-Week Low$6.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.06
    SMA 20$7.19
    SMA 50$8.19
    SMA 200$10.96
    EMA 10$7.22
    EMA 20$7.38
    EMA 50$8.17
    EMA 200$10.03

    MACD

    Line: -0.31Signal: -0.42Hist: 0.12

    ADX

    ADX: 23.4+DI: 22.0-DI: 20.9

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down72.0
    PSAR$6.69

    Bollinger Bands

    Upper Band$7.74
    Lower Band$6.64
    %B Position1529%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    48.9

    Momentum Oscillators

    Stoch %K68.0
    Stoch %D58.2
    Williams %R-18.3
    ROC (10d)5.9%
    Momentum0.42
    CCI (20d)107.7
    MFI (14d)49.4

    Volatility Measures

    ATR (14d)$0.42(5.6%)
    StdDev (20d)0.27
    Hist Vol55.6%(High)

    Volume Flow

    VWAP$7.54
    OBV63.4M
    AD Line-19.9M
    CMF (20d)0.021

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.9x
    VWMA (20d)$7.18

    Pivot Points

    R3$8.58
    R2$8.15
    R1$7.77
    Pivot Point$7.35
    S1$6.97
    S2$6.54
    S3$6.17

    Advanced Oscillators

    TSI-20.38
    Ultimate Osc54.6
    KST-157.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$74.27M$58.30M$57.58M$49.50M$39.50M$28.52M$29.66M$16.35M$7.32M$1.91M$682,000$0
    Cost of Revenue$15.10M$12.00M$7.65M$6.19M$5.04M$3.72M$3.81M$2.36M$1.38M$426,000$167,000$0
    Gross Profit$59.18M$46.30M$49.94M$43.31M$34.47M$24.80M$25.85M$14.00M$5.95M$1.49M$515,000$0
    Operating Expenses$63.14M$61.78M$55.87M$58.59M$94.39M$103.66M$85.27M$84.79M$83.25M$71.44M$70.39M$35.66M
    R&D$7.81M$7.77M$7.49M$7.03M$9.08M$9.18M$8.58M$8.69M$7.38M$9.43M$13.39M$12.26M
    SG&A$55.33M$54.01M$48.37M$51.56M$85.31M$94.47M$76.68M$76.10M$75.87M$62.01M$57.00M$23.40M
    Operating Income$-3,965,000$-15,477,000$-5,928,000$-15,271,000$-59,924,000$-78,863,000$-59,417,000$-70,796,000$-77,300,000$-69,954,000$-69,875,000$-35,659,000
    Interest Income$1.51M$1.74M$1.20M$1.41M$1.79M$2.64M$3.51M$3.71M$3.62M$4.31M$3.35M$2.72M
    Interest Expense$15.10M$15.80M$16.42M$16.11M$17.52M$18.07M$18.59M$18.48M$17.76M$17.17M$13.03M$10.11M
    Income Before Tax$-17,582,000$-30,369,000$-21,148,000$-29,973,000$-75,810,000$-94,316,000$-74,451,000$-85,577,000$-91,446,000$-82,852,000$-79,570,000$-43,243,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,582,000$-30,369,000$-21,148,000$-29,973,000$-75,810,000$-94,316,000$-74,451,000$-85,577,000$-91,446,000$-82,852,000$-79,570,000$-43,243,000
    EBITDA$-2,963,000$-15,354,000$-4,997,000$-14,347,000$-59,173,000$-78,012,000$-58,546,000$-70,024,000$-76,609,000$-69,309,000$-69,138,000$-35,193,000
    EBIT$-3,989,000$-16,308,000$-5,934,000$-15,278,000$-60,079,000$-78,885,000$-59,368,000$-70,804,000$-77,306,000$-69,997,000$-69,889,000$-35,856,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHAT

    News

    Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook

    Jefferies has lowered its price target for Phathom Pharmaceuticals (NASDAQ:PHAT) to $16 from $20, while maintaining a Buy rating, due to a challenging year for the stock...

    Investing.com•10/14/26•Neutral

    Behavioral Patterns of PHAT and Institutional Flows

    This article provides an AI-driven analysis of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), highlighting a near-term strong sentiment that challenges persistent mid and long-term weakness. It identifies an 81.5:1...

    Stock Traders Daily•10/13/26•Somewhat-Bullish

    Phathom Pharmaceuticals Highlights New Cost-Effectiveness

    Phathom Pharmaceuticals presented new cost-effectiveness data and clinical insights for its drug VOQUEZNA (vonoprazan) at the ACG 2026 Annual Scientific Meeting. A new analysis suggests VOQUEZNA is cost-effective...

    GlobeNewswire•10/12/26•Bullish

    Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com

    This article announces the filing of a Form 4 for Phathom Pharmaceuticals Inc., dated October 8. It indicates that the company's stock, PHAT...

    Investing.com India•10/8/26•Neutral

    Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com

    This article from Investing.com reports on a Form 4 filing for Phathom Pharmaceuticals Inc. dated October 8. It indicates a news publication date of October 08, 2026...

    Investing.com Canada•10/8/26•Neutral

    PHAT Valuation and Fair Value

    P/E
    -13.2x
    Forward P/E
    6.6x
    P/FCF
    -17.0x
    P/B
    -1.8x
    See GNG's fair value

    PHAT Profitability: Margins, ROIC and FCF

    Gross margin
    82.9%
    Operating margin
    -5.3%
    Net margin
    -41.3%
    ROIC
    18.2%
    ROE
    -3489.0%
    FCF margin
    -15.4%
    FCF yield
    -5.9%

    PHAT Competitors

    CompanyTicker
    Sophia Genetics SASOPH
    Olema Pharmaceuticals IncOLMA
    ProKidney Corp.PROK
    Ironwood Pharmaceuticals IncIRWD
    Zevra Therapeutics Inc.ZVRA
    Weave Communications IncWEAV
    SurModics IncSRDX
    Nuvectis Pharma IncNVCT

    Sector: Healthcare

    PHAT Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    8
    Hold
    2
    Sell
    0
    Strong Sell
    0

    PHAT Bull Case vs Bear Case

    Bull case

    • PHAT earns an 18.2% return on invested capital.
    • PHAT beat EPS estimates in 75.0% of its last 8 reported quarters.
    • PHAT grew quarterly revenue 88.0% year over year.

    Bear case

    • PHAT has a -41.3% net profit margin.

    PHAT Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    26.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.04
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About PHAT

    Does PHAT pay dividends?

    Phathom Pharmaceuticals Inc (PHAT) does not currently pay a regular dividend.

    What is PHAT's market cap?

    Phathom Pharmaceuticals Inc (PHAT) has a market capitalization of $598.67M with a current stock price of $7.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In